MAPK8 and Familial prostate cancer: Despite many studies reporting on the efficiency of JNK inhibition as an option to suppress prostate cancer progression and metastasis using the inhibitor SP600125, the use of JNK inhibitors as a clinical trial therapeutic option is premature [61].